Enara Bio participates in Boehringer Ingelheim’s “Taking Cancer On” podcast series
Oxford and London, UK – 21 June 2021. Enara Bio, a biotechnology company leveraging its proprietary T-cell/T-cell receptor (TCR) and Dark Antigen™ discovery platforms to deliver targeted cancer immunotherapies, is pleased to have participated in Boehringer Ingelheim’s “Taking Cancer On” podcast series, launched today.
Hosted by Sebastian Hermelin (co-founder of the “War On Cancer” app), each episode welcomes new expert guests who take the listener through one of the many stages of cancer research and drug development; from early discovery efforts, through to clinical trials and drug approval.
In Episode 3 of the series, entitled “Collaborating Against Cancer,” expert guests Scott DeWire, Ph.D., Head of US Business Development at Boehringer Ingelheim and Andrew Fadden, Ph.D., Vice President, Corporate Development at Enara Bio discuss the power of research partnerships in accessing and progressing innovation for cancer drug development. Their discussion proves that embracing collaboration is essential in delivering ground-breaking treatments to patients, faster.
The episode covers the rationale and process that led to the strategic partnership between Boehringer Ingelheim and Enara Bio, announced in early 2021. The speakers describe the focus on the discovery of novel shared antigens for cancer immunotherapies, the important contribution of patients to research, pharmaceutical partnerships in general and the partnering philosophies of the two companies. They also express their gratitude to those who have contributed to the process of developing new therapies to help patients.Listen to the podcast Download the press release
About Enara Bio
Enara Bio is a science-led company targeting the T-cell/cancer-cell interface (the “immune synapse”) to develop new targeted cancer immunotherapies designed to treat a broad patient population. Enara Bio is exploring the hidden depths of cancer and T-cell biology to discover and characterize novel immunotherapy targets, such as Dark Antigens™ and MR1-presented ligands. We are pioneering approaches to exploit these targets with TCR-directed T-cell immunotherapy and therapeutic vaccines. To achieve our mission, we are leveraging our differentiated Dark Antigen™ and TCR discovery platforms that integrate bioinformatics, immunopeptidomics, metabolomics and immunology in our Oxford, UK-based research lab. Enara Bio is backed by leading life science investors, including SV Health Investors. We have partnerships with world-class academic institutions, including the Francis Crick Institute, Cardiff University, Johns Hopkins School of Medicine and the University of Oxford, to help drive the leading edge of these new areas of science.
For more information visit: www.enarabio.com
FOR MORE INFORMATION
Enara Bio Limited
Kevin Pojasek, CEO
Tel: +44(0)1865 618 828
Mark Swallow, Frazer Hall
Tel: +44 (0)20 7638 9571